Cargando…

Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome

The morphologic spectrum of type 1 papillary renal cell carcinoma (PRCC) is not well-defined, since a significant proportion of cases have mixed type 1 and 2 histology. We analyzed 199 cases of PRCC with any (even if focal) type 1 features, with a median follow-up of 12 years, to identify clinicopat...

Descripción completa

Detalles Bibliográficos
Autores principales: Murugan, Paari, Jia, Liwei, Dinatale, Renzo G., Assel, Melissa, Benfante, Nicole, Al-Ahmadie, Hikmat A, Fine, Samson W., Gopalan, Anuradha, Sarungbam, Judy, Sirintrapun, S. Joseph, Hakimi, A. Ari, Russo, Paul, Chen, Ying-Bei, Tickoo, Satish K., Reuter, Victor E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177523/
https://www.ncbi.nlm.nih.gov/pubmed/34949764
http://dx.doi.org/10.1038/s41379-021-00990-9
_version_ 1784722902703144960
author Murugan, Paari
Jia, Liwei
Dinatale, Renzo G.
Assel, Melissa
Benfante, Nicole
Al-Ahmadie, Hikmat A
Fine, Samson W.
Gopalan, Anuradha
Sarungbam, Judy
Sirintrapun, S. Joseph
Hakimi, A. Ari
Russo, Paul
Chen, Ying-Bei
Tickoo, Satish K.
Reuter, Victor E.
author_facet Murugan, Paari
Jia, Liwei
Dinatale, Renzo G.
Assel, Melissa
Benfante, Nicole
Al-Ahmadie, Hikmat A
Fine, Samson W.
Gopalan, Anuradha
Sarungbam, Judy
Sirintrapun, S. Joseph
Hakimi, A. Ari
Russo, Paul
Chen, Ying-Bei
Tickoo, Satish K.
Reuter, Victor E.
author_sort Murugan, Paari
collection PubMed
description The morphologic spectrum of type 1 papillary renal cell carcinoma (PRCC) is not well-defined, since a significant proportion of cases have mixed type 1 and 2 histology. We analyzed 199 cases of PRCC with any (even if focal) type 1 features, with a median follow-up of 12 years, to identify clinicopathological features associated with outcome. Ninety-five tumors (48%) of the cohort contained some type 2 component (median amount: 25%; IQR: 10%, 70%). As a group they showed high rates of progression-free (PFS) and cancer-specific survival (CSS). Tumor size, mitotic rate, lymphovascular invasion, sarcomatoid differentiation, sheet-like architecture, and lack of tumor circumscription were significantly associated with CSS (p≤0.015) on univariate analysis. While predominant WHO/ISUP nucleolar grade was associated with PFS (p=0.013) and CSS (p=0.030), the presence of non-predominant (<50%) nucleolar grade did not show association with outcome (p=0.7). PFS and CSS showed no significant association with the presence or the amount of type 2 morphology. We compared the molecular alterations in paired type 1 and type 2 areas in a subset of 22 cases with mixed type 1 and 2 features and identified 12 recurrently mutated genes including TERT, ARID1A, KDM6A, KMT2D, NFE2L2, MET, APC, and TP53. Among 78 detected somatic mutations, 61 (78%) were shared between the paired type 1 and type 2 areas. Copy number alterations, including chromosome 7 and 17 gains, were similar between type 1 and 2 areas. These findings support that type 2 features in a PRCC with mixed histology represent either morphologic variance or clonal evolution. Our study underscores the notion that PRCC with any classic type 1 regions is best considered as type 1 PRCC and assigned the appropriate WHO/ISUP nucleolar grade. It provides additional evidence that type 2 PRCC as a separate category should be re-assessed and likely needs to be abandoned.
format Online
Article
Text
id pubmed-9177523
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-91775232022-06-23 Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome Murugan, Paari Jia, Liwei Dinatale, Renzo G. Assel, Melissa Benfante, Nicole Al-Ahmadie, Hikmat A Fine, Samson W. Gopalan, Anuradha Sarungbam, Judy Sirintrapun, S. Joseph Hakimi, A. Ari Russo, Paul Chen, Ying-Bei Tickoo, Satish K. Reuter, Victor E. Mod Pathol Article The morphologic spectrum of type 1 papillary renal cell carcinoma (PRCC) is not well-defined, since a significant proportion of cases have mixed type 1 and 2 histology. We analyzed 199 cases of PRCC with any (even if focal) type 1 features, with a median follow-up of 12 years, to identify clinicopathological features associated with outcome. Ninety-five tumors (48%) of the cohort contained some type 2 component (median amount: 25%; IQR: 10%, 70%). As a group they showed high rates of progression-free (PFS) and cancer-specific survival (CSS). Tumor size, mitotic rate, lymphovascular invasion, sarcomatoid differentiation, sheet-like architecture, and lack of tumor circumscription were significantly associated with CSS (p≤0.015) on univariate analysis. While predominant WHO/ISUP nucleolar grade was associated with PFS (p=0.013) and CSS (p=0.030), the presence of non-predominant (<50%) nucleolar grade did not show association with outcome (p=0.7). PFS and CSS showed no significant association with the presence or the amount of type 2 morphology. We compared the molecular alterations in paired type 1 and type 2 areas in a subset of 22 cases with mixed type 1 and 2 features and identified 12 recurrently mutated genes including TERT, ARID1A, KDM6A, KMT2D, NFE2L2, MET, APC, and TP53. Among 78 detected somatic mutations, 61 (78%) were shared between the paired type 1 and type 2 areas. Copy number alterations, including chromosome 7 and 17 gains, were similar between type 1 and 2 areas. These findings support that type 2 features in a PRCC with mixed histology represent either morphologic variance or clonal evolution. Our study underscores the notion that PRCC with any classic type 1 regions is best considered as type 1 PRCC and assigned the appropriate WHO/ISUP nucleolar grade. It provides additional evidence that type 2 PRCC as a separate category should be re-assessed and likely needs to be abandoned. 2022-06 2021-12-23 /pmc/articles/PMC9177523/ /pubmed/34949764 http://dx.doi.org/10.1038/s41379-021-00990-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: https://www.springernature.com/gp/open-research/policies/accepted-manuscript-terms
spellingShingle Article
Murugan, Paari
Jia, Liwei
Dinatale, Renzo G.
Assel, Melissa
Benfante, Nicole
Al-Ahmadie, Hikmat A
Fine, Samson W.
Gopalan, Anuradha
Sarungbam, Judy
Sirintrapun, S. Joseph
Hakimi, A. Ari
Russo, Paul
Chen, Ying-Bei
Tickoo, Satish K.
Reuter, Victor E.
Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title_full Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title_fullStr Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title_full_unstemmed Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title_short Papillary Renal Cell Carcinoma: A Single Institutional Study of 199 Cases Addressing Classification, Clinicopathologic and Molecular Features, and Treatment Outcome
title_sort papillary renal cell carcinoma: a single institutional study of 199 cases addressing classification, clinicopathologic and molecular features, and treatment outcome
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9177523/
https://www.ncbi.nlm.nih.gov/pubmed/34949764
http://dx.doi.org/10.1038/s41379-021-00990-9
work_keys_str_mv AT muruganpaari papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT jialiwei papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT dinatalerenzog papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT asselmelissa papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT benfantenicole papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT alahmadiehikmata papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT finesamsonw papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT gopalananuradha papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT sarungbamjudy papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT sirintrapunsjoseph papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT hakimiaari papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT russopaul papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT chenyingbei papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT tickoosatishk papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome
AT reutervictore papillaryrenalcellcarcinomaasingleinstitutionalstudyof199casesaddressingclassificationclinicopathologicandmolecularfeaturesandtreatmentoutcome